Gateway Wealth Partners LLC Makes New $705,000 Investment in Novartis AG $NVS

Gateway Wealth Partners LLC bought a new stake in Novartis AG (NYSE:NVS) during the first quarter, HoldingsChannel.com reports. The institutional investor bought 4,616 shares of the company’s stock, valued at approximately $705,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Brighton Jones LLC grew its position in Novartis by 76.5% during the fourth quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock worth $599,000 after buying an additional 2,666 shares during the period. AQR Capital Management LLC increased its holdings in Novartis by 102.8% in the first quarter. AQR Capital Management LLC now owns 22,573 shares of the company’s stock valued at $2,516,000 after buying an additional 11,444 shares in the last quarter. Empowered Funds LLC acquired a new stake in shares of Novartis during the 1st quarter valued at approximately $1,764,000. Sivia Capital Partners LLC boosted its stake in shares of Novartis by 48.0% during the 2nd quarter. Sivia Capital Partners LLC now owns 7,959 shares of the company’s stock worth $963,000 after acquiring an additional 2,581 shares in the last quarter. Finally, Schnieders Capital Management LLC. purchased a new stake in shares of Novartis during the 2nd quarter worth approximately $202,000. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Weiss Ratings restated a “buy (b)” rating on shares of Novartis in a report on Friday, July 24th. Citigroup reiterated a “buy” rating on shares of Novartis in a research report on Wednesday, July 22nd. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $141.20.

Novartis Stock Down 0.6%

Shares of NYSE NVS opened at $158.82 on Thursday. Novartis AG has a 12-month low of $112.34 and a 12-month high of $170.46. The company has a market capitalization of $303.06 billion, a PE ratio of 23.96, a price-to-earnings-growth ratio of 2.75 and a beta of 0.45. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.86 and a quick ratio of 0.67. The firm’s 50-day moving average is $152.44 and its two-hundred day moving average is $152.58.

Novartis (NYSE:NVS) last released its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. The business had revenue of $14.95 billion for the quarter. Equities analysts anticipate that Novartis AG will post 8.8 EPS for the current fiscal year.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.